Introduction to Alecensa Indication Expansion  According to a news article (中外製薬　アレセンサで小児含むALK陽性固形がんの適応拡大を申請 | ニュース | ミクスOnline) published by MIX Online on June 27, 2025, Chugai Pharmaceutical has submitted a supplemental application to expand the indication of Alecensa (alectinib hydrochloride) to include unresectable, advanced, or recurrent solid tumors harboring ALK fusion genes, including pediatric patients. If approved, […]